Danaher Corporation (NYSE:DHR) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. trimmed its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 18.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 208,422 shares of the conglomerate's stock after selling 47,619 shares during the quarter. Federated Hermes Inc.'s holdings in Danaher were worth $42,727,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after buying an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP grew its holdings in Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after buying an additional 1,601,800 shares in the last quarter. Capital World Investors grew its holdings in Danaher by 32.7% in the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after buying an additional 1,566,658 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Danaher by 460.6% in the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock valued at $309,558,000 after buying an additional 1,107,998 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Danaher in the 4th quarter valued at $242,837,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Down 0.0%

DHR traded down $0.08 during mid-day trading on Friday, hitting $197.08. 5,736,543 shares of the stock were exchanged, compared to its average volume of 4,375,955. The firm's fifty day moving average is $197.25 and its two-hundred day moving average is $202.96. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a market cap of $141.12 billion, a PE ratio of 41.93, a PEG ratio of 2.74 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the prior year, the company earned $1.72 EPS. Danaher's revenue was up 3.4% on a year-over-year basis. Equities analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 25th. Shareholders of record on Friday, June 27th were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher's dividend payout ratio is currently 27.23%.

Analysts Set New Price Targets

Several brokerages have issued reports on DHR. JPMorgan Chase & Co. dropped their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Tuesday, April 22nd. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Wolfe Research lowered their price target on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a report on Monday, April 7th. UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Finally, The Goldman Sachs Group lowered their price target on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $247.61.

Insider Transactions at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.